Sanofi partners with AI firm Exscientia to develop up to 15 new drugs

Published by
Reuters UK

(Reuters) – French drugmaker Sanofi SA will partner with British AI firm Exscientia Plc to develop up to 15 drug candidates across oncology and immunology, in a deal worth up to $5.2 billion in milestone payments, the two companies said on Friday. Exscientia will get an upfront cash payment of $100 million, leading discovery and design of small molecule drugs up to nomination of the candidate most likely to be viable. After that, Sanofi will take charge of clinical development. Sanofi is among the many pharmaceutical giants venturing into artificial intelligence to improve accuracy and reduce …

Read More